Wortmannin
别名: KY 12420, SL-2052, BRN 0067676, NSC 627609
中文名称:渥曼青霉素
目录号:S2758 Purity: 99.97%
Wortmannin是一种首次命名的PI3K抑制剂,在无细胞试验中IC50为3 nM,对 PI3K 家族的选择性较低。Wortmannin 可抑制自噬体的形成,并有效抑制DNA-PK/ATM,在无细胞试验中IC50为16 nM和150 nM。Wortmannin 也能抑制 PLK1 的活性。
CAS: 19545-26-7
客户使用Selleck的Wortmannin发表文献322篇
- Nature, 2024 10.1038/s41586-024-07990-0
- Signal Transduct Target Ther, 2021 6(1):152
- Signal Transduct Target Ther, 2021 6(1):333
- Nature, 2020 10.1038/s41586-020-2928-y
- Cell, 2019 176(6):1379-1392
- Cancer Discov, 2019 9(5):605-616
- Nat Cell Biol, 2019 21(2):226-237
- Science, 2016 353(6302):929-32
- Nature, 2015 10.1038/nature14412
- Cancer Discov, 2015 5(11):1194-209
- Nat Commun, 2024 15(1):451
- Nat Commun, 2024 15(1):4926
- Theranostics, 2024 14(13):5123-5140
- EMBO Mol Med, 2024 10.1038/s44321-024-00136-9
- J Nanobiotechnology, 2024 22(1):551
- Phytomedicine, 2024 132:155892
- Elife, 2024 12RP90532
- Mol Oncol, 2024 10.1002/1878-0261.13716
- J Virol, 2024 e0068524.
- Sci Rep, 2024 14(1):9070
- Physiol Rep, 2024 12(16):e70001
- Mol Cell Oncol, 2024 11(1):2377404
- J Exp Med, 2023 220(9)e20230054
- Autophagy, 2023 19(4):1164-1183
- Cell Rep, 2023 42(6):112647
- Br J Cancer, 2023 128(1):148-159
- J Cell Biol, 2023 222(9)e202208047
- J Transl Med, 2023 21(1):89
- Int J Mol Sci, 2023 24(4)3823
- Mar Drugs, 2023 21(2)77
- J Cell Mol Med, 2023 27(23):3760-3772
- Development, 2023 150(21)dev201811
- Sci Rep, 2023 13(1):12424
- Pflugers Arch, 2023 475(3):405-416
- Oncol Rep, 2023 50(6)216
- Infect Immun, 2023 91(9):e0006623
- Exp Ther Med, 2023 26(5):516
- BMC Vet Res, 2023 19(1):60
- Sci Adv, 2023 9(33):eadf5142
- Res Sq, 2023 rs.3.rs-3376558
- bioRxiv, 2023 2023.03.23.534007
- Nat Commun, 2022 13(1):2111
- Cancer Res, 2022 canres.2292.2021
- Proc Natl Acad Sci U S A, 2022 119(3)e2114134119
- Clin Transl Med, 2022 12(6):e901
- J Nanobiotechnology, 2022 20(1):270
- J Nanobiotechnology, 2022 20(1):149
- Acta Biomater, 2022 S1742-7061(22)00458-5
- Cell Rep, 2022 38(7):110373
- Cell Rep, 2022 38(11):110522
- Acta Pharmacol Sin, 2022 10.1038/s41401-022-00909-3
- Front Immunol, 2022 13:984520
- Oncoimmunology, 2022 11(1):2109861
- Antioxidants -Basel, 2022 11-91741
- Mol Oncol, 2022 10.1002/1878-0261.13229
- mBio, 2022 13(3):e0081922
- Int J Mol Sci, 2022 23(22)13673
- Int J Mol Sci, 2022 23(21)13014
- Int J Mol Sci, 2022 23(18)10854
- Int J Mol Sci, 2022 23(14)7724
- Int J Mol Sci, 2022 23(13)7359
- Int J Mol Sci, 2022 23(16)8856
- J Virol, 2022 96(14):e0075922
- Mar Drugs, 2022 20(6)378
- Mol Cancer Res, 2022 20(1):161-175
- Mol Nutr Food Res, 2022 e2200186
- Mol Cell Biochem, 2022 10.1007/s11010-022-04413-4
- Toxins (Basel), 2022 14(3)164
- BMC Cancer, 2022 22(1):1193
- Biomol Ther (Seoul), 2022 30(4):348-359
- J Periodontal Res, 2022 57(4):859-868
- World J Biol Psychiatry, 2022 1-17
- J Cardiovasc Pharmacol, 2022 80(3):442-452
- Korean J Physiol Pharmacol, 2022 26(4):255-262
- J Extracell Vesicles, 2021 10(8):e12091
- Adv Sci (Weinh), 2021 e2004303
- J Am Chem Soc, 2021 10.1021/jacs.1c05386
- Biomaterials, 2021 271:120720
- Theranostics, 2021 11(5):2364-2380
- Proc Natl Acad Sci U S A, 2021 118(19)e2017645118
- Sci Total Environ, 2021 775:145814
- Environ Pollut, 2021 275:116636
- Oncogene, 2021 40(6):1128-1146
- Aging Cell, 2021 e13522
- Elife, 2021 10e69047
- Clin Sci (Lond), 2021 135(4):597-611
- Int J Mol Sci, 2021 22(21)11864
- Int J Mol Sci, 2021 22(24)13352
- Front Chem, 2021 9:717904
- FEBS J, 2021 10.1111/febs.15763
- Front Cell Neurosci, 2021 15:768364
- Aging (Albany NY), 2021 13(3):3443-3458
- Biochim Biophys Acta Mol Cell Biol Lipids, 2021 1866(6):158920
- Front Oncol, 2021 11:631766
- Sci Rep, 2021 11(1):11234
- Environ Toxicol Pharmacol, 2021 83:103586
- J Periodontol, 2021 10.1002/JPER.21-0227
- Neurochem Int, 2021 150:105187
- Front Physiol, 2021 12:717119
- Biosci Rep, 2021 41(10)BSR20211056
- Int J Biochem Cell Biol, 2021 134:105952
- Vet Microbiol, 2021 257:109068
- Exp Brain Res, 2021 10.1007/s00221-021-06111-x
- Small, 2020 10.1002/smll.201906360
- Emerg Microbes Infect, 2020 9(1):1748-1760
- J Exp Clin Cancer Res, 2020 39(1):174
- Cancer Res, 2020 80(22):5035-5050
- Cell Death Dis, 2020 11(6):462
- Cell Rep, 2020 33(1):108211
- Cell Rep, 2020 32(5):107982
- Elife, 2020 9
- Elife, 2020 9e56773
- Antiviral Res, 2020 185:104993
- Biomed Pharmacother, 2020 121:109669
- Sci Signal, 2020 13(637):eaba8627
- Eur-J-Med-Chem, 2020 15;188:111976
- Antioxid Redox Signal, 2020 10.1089/ars.2019.7840
- Commun Biol, 2020 3(1):117
- Cancer Immunol Immunother, 2020 10.1007/s00262-020-02700-x
- Mol Cancer Ther, 2020 molcanther.0182.2020
- Front Pharmacol, 2020 11:561956
- J Cell Physiol, 2020 10.1002/jcp.30158
- Int Immunopharmacol, 2020 81:106035
- J-Cell-Physiol, 2020 235-7-8-:5811-5822
- J Cell Physiol, 2020 10.1002/jcp.30184
- Int Immunopharmacol, 2020 91:107215
- Am J Physiol Cell Physiol, 2020 318(3):C664-C674
- J Ethnopharmacol, 2020 S0378-8741(20)33532-7
- J Ethnopharmacol, 2020 S0378-8741(20)33542-X
- Front Microbiol, 2020 11:1446
- Am J Physiol Endocrinol Metab, 2020 1;318(5):E613-E624
- FASEB J, 2020 10.1096/fj.202001413R
- Fish Shellfish Immunol, 2020 98:908-916
- Sci Rep, 2020 10(1):614
- Sci Rep, 2020 10(1):13110
- Neurochem Res, 2020 10.1007/s11064-020-03073-4
- Oncol-Rep, 2020 43-4-:1169-1186
- Int J Med Microbiol, 2020 310(8):151463
- Biosci Rep, 2020 BSR20202388
- J Cell Sci, 2020 11 pii: jcs
- Brain Res Bull, 2020 158:99-107
- Int J Med Sci, 2020 17(18):3174-3189
- Mol Pharmacol, 2020 97(3):145-158
- Cancer Manag Res, 2020 12:6563-6573
- Prostate, 2020 10.1002/pros.24065
- J Physiol Sci, 2020 9;70(1):29
- Sci Adv, 2020 6(29):eaba1941
- Sci Adv, 2020 1;6(18):eaaz7001
- Nat Plants, 2019 5(2):212-224
- J Clin Invest, 2019 1;129(2):676-693
- Adv Sci (Weinh), 2019 6(8):1801233
- Biomaterials, 2019 216:119248
- Autophagy, 2019 1-21
- Theranostics, 2019 9(15):4375-4390
- Theranostics, 2019 9(3):900-919
- Dev Cell, 2019 51(2):236-254
- Pharmacol Res, 2019 148:104368
- Cell Death Dis, 2019 10(6):399
- Cell Rep, 2019 29(4):860-872
- Arterioscler Thromb Vasc Biol, 2019 39(3):496-512
- Cell Prolif, 2019 52(3):e12575
- Cell Commun Signal, 2019 17(1):22
- Acta Pharmacol Sin, 2019 10.1038/s41401-019-0253-5
- Diabetes, 2019 68(8):1635-1648
- Cell Biosci, 2019 9:20
- Free Radic Biol Med, 2019 141:21-33
- Front Immunol, 2019 10:2636
- Front Immunol, 2019
- Oncogenesis, 2019 8(7):38
- Life Sci, 2019 218:300-307
- Life Sci, 2019 222:195-202
- Arch Toxicol, 2019 93(3):709-726
- Int Immunopharmacol, 2019 69:88-94
- J Cell Physiol, 2019 234(4):4504-4514
- J Cell Physiol, 2019 10.1002/jcp.29345
- Front Pharmacol, 2019 10:999
- Nanomedicine (Lond), 2019 14(3):335-351
- Front Cell Dev Biol, 2019 7:204
- Int J Mol Med, 2019 43(1):294-304
- Int J Mol Med, 2019 44(3):982-994
- J Cell Mol Med, 2019 23(2):920-933
- Int J Oncol, 2019 54(3):1061-1070
- Chem Biol Interact, 2019 310:108741
- Am J Physiol Endocrinol Metab, 2019 316(6):E987-E997
- Lab Invest, 2019 10.1038/s41374-019-0256-3
- J Biol Chem, 2019 294(17):7037-7045
- Cell Signal, 2019 54:170-178
- J Biol Chem, 2019 294(21):8384-8394
- Neuropharmacology, 2019 148:31-39
- Sci Rep, 2019 9(1):4360
- IUBMB Life, 2019 10.1002/iub.2104
- J Immunol, 2019 203(6):1579-1588
- Invest Ophthalmol Vis Sci, 2019 60(4):1156-1164
- Cell Cycle, 2019 18(21):2928-2938
- Front Physiol, 2019 0.57152777778
- J Cell Biochem, 2019 120(3):3082-3090
- J Cell Biochem, 2019 120(8):12989-13000
- J Endocrinol, 2019 240(2):195-214
- Cell Biol Int, 2019 10.1002/cbin.11199
- Toxicol Appl Pharmacol, 2019 381:114729
- J Mol Endocrinol, 2019 63(3):199-213
- Free Radic Res, 2019 53(3):348-358
- Biochem Biophys Res Commun, 2019 516(1):209-214
- Brain Res, 2019 1719:64-70
- Evid Based Complement Alternat Med, 2019 2019:5789574
- Exp Physiol, 2019 104(5):704-714
- Nat Commun, 2018 9(1):5009
- Biomaterials, 2018 161:228-239
- J Control Release, 2018 273:40-50
- Cell Death Dis, 2018 9(3):269
- Cell Death Dis, 2018 9(6):604
- Environ Pollut, 2018 233:889-899
- Acta Pharmacol Sin, 2018 39(1):97-106
- Sci Signal, 2018 11(523)eaao1052
- Ecotoxicol Environ Saf, 2018 165:144-152
- Am J Pathol, 2018 188(12):2924-2935
- Front Pharmacol, 2018 9:760
- J Am Heart Assoc, 2018 7(3)
- J Virol, 2018 92(8)
- Chem Biol Interact, 2018 296:26-33
- Mol Neurobiol, 2018 55(5):3946-3958
- J Hypertens, 2018 36(3):651-665
- FASEB J, 2018 10.1096/fj.201800109R
- Front Mol Neurosci, 2018 11:198
- Endocrinology, 2018 159(1):285-296
- Viruses, 2018 10(5)E259
- Reprod Biol Endocrinol, 2018 16(1):50
- Mol Cell Endocrinol, 2018 474:20-34
- Cancer Med, 2018 7(4):1317-1325
- NPJ Syst Biol Appl, 2018 4:1
- Onco Targets Ther, 2018 11:4221-4232
- BMC Complement Altern Med, 2018 18(1):142
- PLoS One, 2018 13(12):e0208427
- Cancer Biol Ther, 2018 19(7):584-589
- Gene, 2018
- Mol Med Rep, 2018 18(5):4259-4270
- Biochem Biophys Res Commun, 2018 503(2):420-427
- BMC Nephrol, 2018 19(1):45
- Int J Ophthalmol, 2018 11(7):1120-1128
- Acta Biol Hung, 2018 69(4):395-410
- Nat Commun, 2017 8:14709
- Nat Commun, 2017 8(1):2118
- Autophagy, 2017 13(3):538-553
- Autophagy, 2017 13(7):1093-1112
- J Thromb Haemost, 2017 15(8):1679-1688
- Cell Death Dis, 2017 8(5):e2765
- Cell Death Dis, 2017 8(7):e2954
- Cell Biosci, 2017 7:43
- Biochim Biophys Acta Mol Basis Dis, 2017 1863(4):991-1001
- Oncotarget, 2017 8(42):71642-71656
- Oncotarget, 2017 8(38):63911-63922
- Oncotarget, 2017 8(58):98471-98481
- Oncotarget, 2017 8(39):66195-66203
- J Cell Mol Med, 2017 21(3):456-466
- Mediators Inflamm, 2017 2017:5706152
- Sci Rep, 2017 7:42678
- Sci Rep, 2017 7(1):15208
- Sci Rep, 2017 7(1):14871
- Sci Rep, 2017 7(1):12307
- Neurochem Res, 2017 42(10):2949-2957
- J Immunol, 2017 198(9):3426-3435
- Cell Physiol Biochem, 2017 42(2):579-593
- J Diabetes Res, 2017 2017:8208065
- Mol Cell Endocrinol, 2017 444:1-8
- Xenotransplantation, 2017 24(4)
- J Mol Endocrinol, 2017 59(2):151-169
- J Pharmacol Sci, 2017 134(4):197-202
- J Physiol Biochem, 2017 73(4):583-594
- eNeuro, 2017 4(3)ENEURO.0354-16.2017
- Biochem Biophys Res Commun, 2017 488(1):116-121
- Biochem Biophys Res Commun, 2017 490(2):385-392
- Med Sci Monit, 2017 23:2035-2041
- Am J Transl Res, 2017 9(5):2077-2087
- Biol Pharm Bull, 2017 40(12):2146-2152
- Nat Commun, 2016 7:13650
- Cell Death Dis, 2016 7:e2216
- Oxid Med Cell Longev, 2016 2016:4856431
- Inflamm Res, 2016 65(3):193-202
- Biofactors, 2016 42(2):212-23
- J Ethnopharmacol, 2016 193:293-302
- Oncotarget, 2016 7(40):65374-65388
- Oncotarget, 2016 7(19):27176-84
- Mol Cell Biol, 2016 36(10):1555-68
- Sci Rep, 2016 6:27332
- Sci Rep, 2016 6:22192
- PLoS Genet, 2016 12(9):e1006311
- Cell Cycle, 2016 15(1):84-94
- Int J Biochem Cell Biol, 2016 80:132-142
- J Gen Virol, 2016 97(11):2824-2836
- Anticancer Res, 2016 36(11):5849-5858
- Korean J Parasitol, 2016 54(2):123-32
- Tumour Biol, 2016 37(1):1025-33
- Cell Rep, 2015 10.1016/j.celrep.2015.01.014
- Elife, 2015 4:e10510
- Cell Death Discov, 2015 1:15057
- Cancer Sci, 2015 106(2):160-70
- J Ethnopharmacol, 2015 172:368-76
- Oncotarget, 2015 6(16):14385-98
- Oncotarget, 2015 6(30):29963-74
- Oncotarget, 2015 6(41):43540-56
- Aging (Albany NY), 2015 7(4):223-32
- Scientific Reports, 2015 5, Article number: 15213
- Sci Rep, 2015 5:15213
- Eur J Pharm Sci, 2015 70C:82-91
- Mol Cell Endocrinol, 2015 405C:63-73
- PLoS One, 2015 10(11):e0141622
- Int J Clin Exp Pathol, 2015 8(11):13821-33
- Cancer Res, 2014 74(10):2846-56
- Cancer Res, 2014 74(16):4282-94
- Transl Res, 2014 164(5):411-23
- Sci Signal, 2014 7(349):ra103
- Mol Cell Proteomics, 2014 13(1):49-62
- Acta Physiol, 2014 212(1):75-85
- Mol Cancer Ther, 2014 13(1):37-48
- Int Immunopharmacol, 2014 24(1): 50-58
- J Funct Foods, 2014 9(10):385-396
- Pigment Cell Melanoma Res, 2014 10.1111/pcmr.12268
- Acta Histochem, 2014 116(5):838-43
- Int J Mol Sci, 2013 14(9):17304-18
- Front Genet, 2013 4:34
- J Cell Sci, 2012 126(Pt 3):715-21
- Cancer Res, 2010 70(12):4982-94
化学信息&溶解度
分子量 | 428.43 |
分子式 | C23H24O8 |
CAS号 | 19545-26-7 |
Smiles | CC(=O)OC1CC2(C(CCC2=O)C3=C1C4(C(OC(=O)C5=COC(=C54)C3=O)COC)C)C |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 85 mg/mL ( 198.39 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 85 mg/mL ( 198.39 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 86 mg/mL ( 200.73 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 85 mg/mL ( 198.39 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5%DMSO
40%PEG300
5%Tween80
50%ddH2O
浓度:5mg/ml
(11.67mM)
操作示例:以 1 mL 工作液为例,取50μL100mg/ml的澄清DMSO储备液加到400μL PEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μL ddH2O定容至 1 mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。